Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas.
Meyer T, Gaya AM, Dancey G, Stratford MR, Othman S, Sharma SK, Wellsted D, Taylor NJ, Stirling JJ, Poupard L, Folkes LK, Chan PS, Pedley RB, Chester KA, Owen K, Violet JA, Malaroda A, Green AJ, Buscombe J, Padhani AR, Rustin GJ, Begent RH. Meyer T, et al. Among authors: chester ka. Clin Cancer Res. 2009 Jul 1;15(13):4484-92. doi: 10.1158/1078-0432.CCR-09-0035. Epub 2009 Jun 23. Clin Cancer Res. 2009. PMID: 19549771 Free article. Clinical Trial.
A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug.
Mayer A, Francis RJ, Sharma SK, Tolner B, Springer CJ, Martin J, Boxer GM, Bell J, Green AJ, Hartley JA, Cruickshank C, Wren J, Chester KA, Begent RH. Mayer A, et al. Among authors: chester ka. Clin Cancer Res. 2006 Nov 1;12(21):6509-16. doi: 10.1158/1078-0432.CCR-06-0769. Clin Cancer Res. 2006. PMID: 17085666 Clinical Trial.
Engineering antibodies for clinical applications in cancer.
Chester K, Pedley B, Tolner B, Violet J, Mayer A, Sharma S, Boxer G, Green A, Nagl S, Begent R. Chester K, et al. Tumour Biol. 2004 Jan-Apr;25(1-2):91-8. doi: 10.1159/000077727. Tumour Biol. 2004. PMID: 15192316 Review.
Antibody-directed enzyme-prodrug therapy.
Pedley RB, Sharma SK, Hawkins RE, Chester KA. Pedley RB, et al. Among authors: chester ka. Methods Mol Med. 2004;90:491-514. doi: 10.1385/1-59259-429-8:491. Methods Mol Med. 2004. PMID: 14657581 No abstract available.
Use of second antibody in radioimmunotherapy.
Begent RH, Bagshawe KD, Pedley RB, Searle F, Ledermann JA, Green AJ, Keep PA, Chester KA, Glaser MG, Dale RG. Begent RH, et al. Among authors: chester ka. NCI Monogr. 1987;(3):59-61. NCI Monogr. 1987. PMID: 3493442
Taking engineered anti-CEA antibodies to the clinic.
Mayer A, Chester KA, Flynn AA, Begent RH. Mayer A, et al. Among authors: chester ka. J Immunol Methods. 1999 Dec 10;231(1-2):261-73. doi: 10.1016/s0022-1759(99)00162-3. J Immunol Methods. 1999. PMID: 10648943 Review.
106 results